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The tyrosine kinase activity of the BCR–ABL oncoprotein results in reduced apoptosis and thus prolongs survival of chronic
myelogenous leukaemia cells. The tyrosine kinase inhibitor imatinib (formerly STI571) was reported to selectively suppress the
proliferation of BCR–ABL-positive cells. Assuming that imatinib could be included in pretransplantation conditioning therapies,
we tested whether combinations of imatinib and g-irradiation or alkylating agents such as busulfan or treosulfan would display
synergistic activity in BCR–ABL-positive chronic myelogenous leukaemia BV173 and EM-3 cell lines. Further, primary cells of
untreated chronic myelogenous leukaemia patients were assayed for colony forming ability under combination therapy with
imatinib. Additionally, the cytotoxic effect of these combinations on BCR–ABL-negative cells was investigated. In the cell lines
a tetrazolium based MTT assay was used to quantify growth inhibition after exposure to cytotoxic drugs alone or to
combinations with imatinib. Irradiation was applied prior to exposure to imatinib. Interaction of drugs was analysed using the
median-effect method of Chou and Talalay. The combination index was calculated according to the classic isobologram
equation. The combination imatinib+g-irradiation proved to be signiﬁcantly synergistic over a broad range of cell growth
inhibition levels in both BCR–ABL-positive cell lines and produced the strongest reduction in primary chronic myelogenous
leukaemia colony-forming progenitor cells. Combinations of imatinib+busulfan and imatinib+treosulfan showed merely
additive to antagonistic effects. Imatinib did not potentiate the effects of irradiation or cytotoxic agents in BCR–ABL-negative
cells. Our data provide the basis to further develop imatinib-containing conditioning therapies for stem cell transplantation in
chronic myelogenous leukaemia.
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Chronic myelogenous leukaemia (CML) is a clonal disorder of the
pluripotent stem cell with involvement of all haemopoietic
lineages and is characterised by preferential expansion of myeloid
cells. On the cellular level, CML is distinguished by the Philadel-
phia chromosome (Nowell and Hungerford, 1960), an abnormally
short chromosome 22, which is found in more than 90% of all
cases of CML, arising from a reciprocal t(9;22) translocation
(Rowley, 1973). The product of this translocation, a 210-kD
BCR–ABL protein (p210
BCR-ABL), is characterised by a constitu-
tively enhanced tyrosine kinase activity as compared with that
of the normal c-ABL protein (Konopka et al, 1984) and is known
to interfere with a variety of cytoplasmatic and cytoskeletal signal-
ling proteins and cascades (Faderl et al, 1999; Deininger et al,
2000), which eventually leads to inhibition of apoptosis. The
inherent resistance of residual BCR–ABL-positive cells to cyto-
toxic therapy is a major impediment to long-term management
of CML.
After a median duration of 2–6 years under conventional ther-
apy, the initial indolent chronic phase of the disease is followed by
the accelerated phase and terminal blast crisis, which results in the
patient’s death within 3–6 months (Kantarjian et al, 1998). Allo-
geneic stem cell transplantation (allo-SCT) still remains the only
proven curative option and particularly younger patients can bene-
ﬁt from this procedure (Gratwohl et al, 1998).
For patients without a suitable donor, high-dose conditioning
therapy followed by autologous SCT (auto-SCT) is an option
and durable remissions can be achieved in patients transplanted
in the early chronic phase (Carella et al, 1999). The value of
auto-SCT as consolidative treatment in blast crisis patients or
patients with BCR–ABL-positive leukaemia transplanted in
remission is the subject of ongoing trials (Goekbuget et al,
2001). Detection of residual leukaemic cells after high-dose
chemotherapy is a strong predictor for clinical relapse in
BCR–ABL-positive disease (van Dongen et al, 1998). Strategies
to improve the conditioning therapy may help to increase the
remission rates.
One of the new and currently very promising therapeutic strate-
gies for CML is the targeting of the BCR–ABL tyrosine kinase
(Druker et al, 1996). Recently reported clinical trials with the Abl
tyrosine kinase inhibitor imatinib in blast crisis (Druker et al,
2001a), interferon-refractory or -intolerant chronic phase (Druker
et al, 2001b), and in accelerated phase CML patients (Talpaz et
al, 2000) showed encouraging results.
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www.bjcancer.comNevertheless, 60% of myeloid blast crisis and almost all
lymphoid blast crisis patients eventually relapsed (Druker et
al, 2001a). Relapses were also observed in the accelerated and
even in the chronic phase of the disease (Gorre et al, 2001;
Hochhaus et al, 2001). Combination of imatinib with estab-
lished cytotoxic therapy especially for the control of minimal
residual disease as can be achieved by marrow-ablative condi-
tioning therapy may allow to further reduce the leukaemic
cell pool.
MATERIALS AND METHODS
Cells
The BCR–ABL-positive BV173 (lymphatic blast crisis) and EM-3
(myeloid blast crisis) human cell lines and the BCR–ABL-negative
KG1a and HL-60 human leukaemic cell lines were obtained from
the German Collection of Microorganisms and Cell Cultures
(Braunschweig, Germany). The BCR–ABL status of the cell lines
was conﬁrmed using reverse transcriptase-polymerase chain reac-
tion (data not shown). Cells were grown in RPMI-1640 medium
supplemented with 10% (BV173, HL-60 and EM-3) or with 20%
(KG1a) heat inactivated foetal calf serum (FCS), 2 mML -gluta-
mine, and penicillin/streptomycin (Life Technologies GmbH,
Eggenstein, Germany) at 378C in a fully humidiﬁed atmosphere
of 95% air and 5% CO2. Primary cells were obtained from two
patients in chronic phase CML. Mononuclear cells were isolated
by Ficoll gradient centrifugation (Biocoll separating solution,
Biochrom KG, Berlin, Germany).
Irradiation and alkylating agents
g-irradiation, busulfan and treosulfan were chosen for combination
treatment in this study. A
138Cs source at a dose-rate of
0.72 Gy min
71 was used for irradiation. The busulfan solution
(Busulfex injection) was obtained from Orphan Medical, Inc.,
Minnetonka, MN, USA, in a 10 ml ampoule containing busulfan
60 mg, dimethylacetamide 3.333 ml and polyethylene glycole
6.667 ml. Treosulfan (Ovastat 1000) was provided by Medac,
Hamburg, Germany. Imatinib was provided by Novartis Pharma
AG, Basel, Switzerland. Serial dilutions of the drugs were prepared
by diluting the stock solutions in sterile Dulbecco’s phosphate
buffered saline (Dulbecco’s PBS, Life Technologies GmbH) freshly
prior to beginning of incubation.
Simultaneous exposure to imatinib in combination with busul-
fan or treosulfan was chosen to ensure a continuous inhibition
of the BCR–ABL tyrosine kinase. Irradiation was applied prior
to incubation with imatinib. Cells were either treated with six
increasing doses (doubling with each increment) of busulfan, treo-
sulfan, irradiation or imatinib alone or with the respective
combinations. The doses for BV173 cells are given in Table 1.
For EM-3 cells following dose ranges were used: g-irradiation
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Table 1 Growth inhibition of BCR–ABL-positive BV173 cells by combinations of imatinib with g-irradiation,
busulfan or treosulfan (MTT assay)
Imatinib (mM)
0 0.025 0.05 0.1 0.2 0.4 0.8
A
Irradiation (Gy)
0 0 0.047 0.078 0.173 0.459 0.710 0.816
0.375 0.143 0.256 0.312 0.484 0.672 0.833 0.903
0.75 0.265 0.374 0.465 0.583 0.778 0.888 0.937
1.5 0.520 0.596 0.666 0.786 0.884 0.955 0.973
3 0.743 0.768 0.808 0.863 0.941 0.977 0.985
6 0.910 0.957 0.964 0.980 0.990 0.993 0.992
12 0.956 0.986 0.990 0.991 0.994 0.996 0.994
B
Busulfan (mM)
0 0 0.007 0.035 0.146 0.431 0.665 0.736
10 0.010 0.012 0.037 0.200 0.496 0.674 0.768
20 0.011 0.020 0.059 0.240 0.513 0.705 0.778
40 0.092 0.103 0.143 0.352 0.616 0.752 0.811
80 0.376 0.432 0.449 0.577 0.726 0.865 0.917
160 0.853 0.888 0.858 0.908 0.972 0.992 0.997
320 0.995 0.997 0.998 0.998 0.996 0.997 0.996
C
Treosulfan (mM)
0 0 0.041 0.067 0.111 0.343 0.648 0.800
1 0.005 0.055 0.053 0.210 0.461 0.732 0.832
2 0.096 0.185 0.196 0.367 0.543 0.754 0.864
4 0.411 0.543 0.585 0.725 0.788 0.845 0.921
8 0.791 0.865 0.866 0.891 0.929 0.932 0.953
16 0.909 0.960 0.959 0.962 0.970 0.973 0.980
32 0.944 0.985 0.980 0.983 0.983 0.986 0.987
The tests with single agents and the respective combinations were carried out simultaneously. The effect of imatinib alone was
determined separately for A, B and C explaining the slightly different values. Numbers represent Fa values (e.g. Fa=0.5 corre-
sponds to 50% growth inhibition). For each monotherapy six different doses and for each combination a total of 36 dose
combinations were tested. All experiments were performed in triplicate. Here, mean values of triplicates are given. Bold
numbers (representing values for equitoxic dose ratio combinations) were selected for further analysis on the basis of the
ED50 values of both single modality treatments: e.g. ED50 of imatinib in A is approximately 0.2 mM,E D 50 of g-irradiation is
approximately 1.5 Gy; the respective approximately equitoxic dose ratio is 0.2 mM/1.5 Gy or 1:7.5. Accordingly, approximately
equitoxic dose ratios of imatinib/busulfan and imatinib/treosulfan are 1:400 and 1:20 (mM/mM), respectively. Together with the
respective Fa values for single modality treatments bold ﬁgures Fa values were used for combination index calculations using the
CalcuSyn software.
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British Journal of Cancer (2002) 86(9), 1487–1493 ã 2002 Cancer Research UK0.75–24 Gy, busulfan 5–160 mM, treosulfan 2–64 mM, and imati-
nib 0.025–0.8 mM.
MTT assay
The MTT assay is based on the cleavage of the yellow tetrazolium
salt 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide
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Figure 1 Example for the dose response curve of irradiation in BCR–
ABL-positive BV173 cells (A) and the data transformation to allow calcula-
tion of the level of growth inhibition at a given dose according to the med-
ian effect equation of Chou and Talalay (B). The dose-response
relationship is displayed as a linear regression line (r=0.997). The x-inter-
cept of the median effect-plot (B) represents the median effect dose
(Dm,E D 50) at which a 50% growth inhibition (Fa=0.5) occurs. The six data
points in A and B correspond to the six original data points of irradiation
alone in Table 1 (1st data column). Fa, affected fraction; Fu, unaffected frac-
tion; D, dose.
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Figure 2 Example of a classic isobologram at ED75. Imatinib is combined
with g-irradiation in BV173 cells. The ED75 values were calculated from a
series of primary data such as presented in Table 1 using CalcuSyn soft-
ware. Means of three experiments were calculated and an isobologram
was drawn by MS Excel. The three data points shown (a, b, and c)
correspond to imatinib [mM]/g-irradiation [Gy] ratios of 1:15, 1:7.5 (ap-
proximately equitoxic combination), and 1:3.75, respectively. The corre-
sponding CI values as calculated following the classic isobologram
equation are 0.572, 0.583, and 0.593. As CI values of 51 express syner-
gism, imatinib+g-rradiation represents an example of a strongly synergistic
combination.
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Figure 3 Combination index (CI) as a function of affected fraction (Fa) in BCR–ABL-positive BV173 (A) and EM-3 (B) cells. Fa values of e.g. 0.25, 0.5 or
0.75 correspond to 25, 50 or 75% growth inhibition. CI values were calculated for distinct Fa values (e.g. Fa 0.1, 0.2, etc.) on the basis of experimentally
determined Fa data such as shown in Table 1. By this method, CI values for different levels of growth inhibition and different drug combinations can easily
be compared. The synergistic activity increases with higher levels of growth inhibition in all combinations (most apparently in the combination g-irradiation
+imatinib) suggesting optimal (maximal) activity of the pro-apoptotic treatment (g-irradiation, busulfan, treosulfan) when imatinib is efﬁciently blocking
BCR–ABL tyrosine kinase activity and the associated anti-apoptotic mechanisms. Solid lines, means; dotted lines, 1 s.d.-range.
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(Mosmann, 1983). A high correlation between the viable cell
number and formazan production has been reported (Finlay et
al, 1986; Pieters et al, 1988). In vitro blast cell survival measured
by the MTT assay correlates highly with blast cell proliferation
measured by the classical
3H-thymidine incorporation assay
(Norgaard et al, 1996). The MTT assay is widely used for assess-
ment of combination therapies employing imatinib (Thiesing et
al, 2000; Kano et al, 2001) and was performed as previously
described (Topaly et al, 2001).
Determination of Combination Index (CI)
Dose-effect relationships were analysed using the median-effect
method (Chou and Talalay, 1984; Topaly et al, 2001), an example
is given in Figure 1. The combination index (CI) was used to
express synergism (CI51), additivity (CI=1) or antagonism
(CI41) and was calculated according to the classic isobologram
equation:
CI  d1=D1  d2=D2 1
In this equation, D1 and D2 represent the doses of drug 1 and
drug 2 alone, required to produce x% effect, and d1 and d2
are the doses of drugs 1 and 2 in combination required to
produce the same effect. Figure 2 illustrates this equation using
three different dose ratio combinations of the two treatment
modalities, each effecting 75% growth inhibition (ED75). Since
different CI values can be observed at different levels of growth
inhibition (fraction affected, Fa), presentation of data in CI vs
affected fraction (Fa) plots is reasonable (Figure 3). CI values
were initially calculated for three separate experiments using
CalcuSyn Software and then transferred to MS Excel for calcula-
tion of mean values and standard deviation (s.d.); Fa-CI plots
were drawn using MS Excel.
CFC Assay
4610
4 (patient 1) or 2610
5 cells (patient 2), cell numbers produ-
cing 50–70 colony-forming units granulocyte/macrophage (CFU–
GM) per plate in untreated controls, were plated in duplicate in
MethoCult GF H4434 methylcellulose (MC; Stem Cell Technolo-
gies, Vancouver, Canada) containing SCF (50 ng ml
71), GM–
CSF (10 ng ml
71), IL-3 (10 ng ml
71), and erythropoetin (3 units
ml
71) and incubated for 14 days at 378C in humidiﬁed
atmosphere containing 5% CO2 as previously described (Kasper
et al, 1999). Individual CFU-GMs were counted. Mean values of
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Figure 4 Apoptosis in EM-3 cells 24 h after start of incubation as de-
tected by the annexin V/propidium iodide assay. Compared to treatment
with imatinib alone or g-irradiation alone (A, imatinib; B, g-irradiation) a
striking increase in the early apoptotic (lower right quadrant: annexin
V+/PI7) and dead cell (upper right quadrant: annexin V+/PI+) fractions
was observed (C) when the cells were treated with the combination. D,
untreated cells.
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the drugs and g-irradiation used in CFC assay are given in
Figure 5.
Apoptosis assay
Annexin V/propidium iodide apoptosis assay was performed
using the Annexin V-FITC Kit (Immunotech, Marseille, France)
24 h after beginning of incubation of EM-3 cells according to
the manufacturer’s protocol. The data were collected and
analysed with a FACScalibur ﬂow cytometer (Becton Dickinson,
Heidelberg, Germany) using the CellQuest Software (Becton
Dickinson).
Statistics
Results are shown as mean values+standard deviation (s.d.) of
three separate experiments. Statistical signiﬁcance of the data was
calculated by Student t-test. A signiﬁcance level of P50.05 was
chosen.
RESULTS
Single agent therapy
ED50 values of imatinib alone were assessed following 48 h of
incubation for all cell lines. The BCR–ABL-positive cell lines
BV173 and EM3 were highly susceptible to imatinib with ED50
values of 0.30+0.08 mM (mean+s.d., n=9) and 0.11+0.03 mM
(n=3), respectively. The ED50 values in BCR–ABL-negative cell
lines HL-60 and KG1a were 17.1+0.7 mM and 26.7+3.3 mM,
respectively. The therapeutic index of imatinib in vitro, deﬁned
as the ratio of ED50 in BCR–ABL-negative cells (dose-limiting
side effect) to ED50 in BCR–ABL-positive cells (therapeutic
effect), ranged from 57 to 243. For assessment of combination
effects in BCR–ABL-negative cells a dose of 1.0 mM imatinib
was used since this concentration failed to measurably affect their
growth while causing more than 80% of growth inhibition in
BV173 and EM-3 cells.
The sensitivity of cells to busulfan was relatively uniform
ranging from an ED50 of 56.2+12.4 mM in HL-60 to
90.8+11.3 mM in BV173 cells. On the contrary, the sensitivity
to g-irradiation varied widely. BV173 cells proved to be most
sensitive (ED50=1.70+0.95 Gy) while in EM-3 cells the ED50
was 6.39+0.69 Gy; in KG1a cells 10 Gy produced only minor
growth inhibition of less than 20%. The ED50 of treosulfan
ranged from 5.03+0.24 mM in BV173 cells to 54.4+3.7 mM in
KG1a cells.
In all experiments the linear correlation coefﬁcient of the
median-effect plot (r) was 40.96 providing a reliable basis for
further calculations.
Combination treatment of BCR–ABL-positive cells
Therapeutic effects of approximately equitoxic molar ratios were
chosen for the assessment of the combination index (CI). Since
each cell line displayed different sensitivity to single modality treat-
ments tested, the equitoxic molar ratios were adjusted individually
for each BCR–ABL-positive cell line (bold numbers in Table 1).
An example of the experimental design is given in Table 1.
Both in BV173 and in EM-3 cells signiﬁcant synergistic effects
(P50.05) of imatinib+g-irradiation were observed. In BV173 cells,
the synergistic effect became apparent already at inhibition levels
above 30% (Fa=0.3) and still increased at higher inhibition levels.
In combinations with busulfan or treosulfan, only additive effects
were observed (Figure 3A).
In EM-3 cells, higher CI values were generally observed with
all combinations tested. A synergism of imatinib+g-irradiation
became apparent at higher levels of growth inhibition than in
BV173 cells (Figure 3B). Combinations with busulfan and treo-
sulfan were again additive or even slightly antagonistic (Figure
3B).
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Figure 6 Effects of g-irradiation, busulfan or treosulfan (each+1.0 mM
imatinib) on BCR–ABL-negative cells: ED50 values of g-irradiation, busulfan
or treosulfan alone and the respective ED50 values in combination with im-
atinib do not differ signiﬁcantly. Addition of imatinib does not increase the
cytotoxicity on BCR–ABL-negative cells. White columns, cytotoxic treat-
ment alone; hatched columns, respective combination with imatinib; bars,
1 s.d. Means of three paired experiments are presented (P40.05).
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ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(9), 1487–1493The annexin V/propidium iodide apoptosis assay showed a
considerable increase of the apoptotic cell fraction in EM-3 cells
treated with imatinib+g-irradiation as compared to treatment with
imatinib or g-irradiation alone (Figure 4). This ﬁnding conﬁrms
that the observed synergism is based on an pro-apoptotic mechan-
ism of action.
In CFC assays with primary CML progenitor cells combination
of imatinib and g-irradiation produced a stronger growth inhibi-
tion than either treatment alone over the whole dose range
tested (Figure 5). Combinations of imatinib+busulfan and imati-
nib+treosulfan were inferior.
Combination treatment of BCR–ABL-negative cells
Since imatinib itself had no measurable effect on BCR–ABL-nega-
tive cells at concentrations up to 1.0 mM, the median-effect method
could not be applied to assess combination effects. Therefore, ED50
values of g-irradiation, busulfan or treosulfan alone were compared
with the respective ED50 values in the presence of 1.0 mM imatinib.
As shown in Figure 6, no increase of g-irradiation-, busulfan- or
treosulfan-induced cytotoxicity by imatinib was observed; the
respective ED50 values were even slightly higher when combined
with imatinib (not signiﬁcant).
DISCUSSION
This study shows a strong synergism of the combination of imati-
nib+g-irradiation in BCR–ABL-positive lymphoid and myeloid
blast crisis cells and its superiority to combinations of imatinib
with the alkylating agents busulfan or treosulfan which were
merely additive. Imatinib+g-irradiation was also the most active
combination against primary colony-forming CML cells. In
BCR–ABL+ cell lines, doses chosen (with the exception of busul-
fan) came close to the clinically relevant dose range; in primary
CML progenitors we chose a dose range of 0.1–2.5 Gy g-irradia-
tion and 0.2–5.0 mM busulfan or treosulfan (Figure 5) which
would be feasible to be used in vivo (Ko ¨rbling et al, 1986; Jacob-
son et al, 2001; Scheulen et al, 2000). Synergistic effects of
imatinib with g-irradiation and chemotherapeutic agents in
leukaemic cell lines correlated well with the effects in primary
CML cells.
In-vitro combination treatment data have already contributed to
the design of current clinical trials with imatinib (Fruehauf and
Hochhaus, 2001; Druker et al, 2001c). Consideration of the present
results for clinical pretransplant conditioning therapy of CML
patients should be discussed.
Since imatinib alone has little or no measurable effect and does
not potentiate the effects of established cytotoxic treatment in
BCR–ABL-negative cells at therapeutically relevant concentrations,
even merely additively acting imatinib-containing combinations as
shown in CML cells should exert more selective toxicity on the
leukaemic cell clone as compared with either chemo- or radio-
therapy alone. Synergistic combinations exert this effect even
stronger.
Total body irradiation (TBI) or busulfan are contained in
marrow ablative conditioning regimens and treosulfan (Loeb,
1964) is being tested in clinical trials in toxicity-reduced condi-
tioning (Casper et al, 2000; Ploemacher et al, 2000). TBI/
cyclophosphamide and busulfan/cyclophosphamide regimens are
used alternatively for pretransplant conditioning therapy. A
synergism between imatinib and mafosfamide, an active form
of cyclophosphamide representing an essential part of the condi-
tioning therapy, has been shown previously (Topaly et al, 2001).
It is controversial which conditioning regimen, TBI/cyclopho-
sphamide or busulfan/cyclophosphamide, should be preferred
for conditioning in the clinical setting. For treatment of BCR–
ABL-positive acute lymphoblastic leukaemia or lymphatic blast
crisis of CML, TBI-containing regimens are generally preferred
due to the higher irradiation sensitivity of lymphoid blasts and
due to the risk of relapse in the central nervous system (Gran-
ados et al, 2000). In the myeloid blast crisis the choice of
regimen is less uniform. Although TBI-containing conditioning
seems to be more toxic as compared to its busulfan-containing
counterpart, the speed of engraftment, event-free survival and
relapse rate are not signiﬁcantly different (Clift et al, 1994).
We hypothesise that in the autologous (Pigneux et al, 1999)
and possibly in the allogeneic transplantation setting TBI/cyclo-
phosphamide+imatinib based on their synergistic effects could
produce superior disease-free survival, even though risks and
beneﬁts should be thoroughly evaluated in future clinical trials.
Treosulfan is employed alternatively to busulfan in conditioning
regimens (Casper et al, 2000) and could also be supplemented
with imatinib in CML patients. As a next step of preclinical test-
ing, these combinations can be assessed in a ‘mock-conditioning’
scenario, i.e. in a mixed population of BCR–ABL-positive and -
negative cells.
In conclusion, this is the ﬁrst report on synergistic interaction
between imatinib and g-irradiation. It highlights the potential of
combination treatment of CML employing speciﬁc BCR–ABL
tyrosine kinase targeting and provides a rationale for the design
of future conditioning protocols for stem cell transplantation in
CML.
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